Clearmind Medicine Inc. (CMND) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, CMND scores 47 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12 / 20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 3 / 20 (institutional accumulation and options positioning), Insider Conviction at 9 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillar is institutional flow (3 / 20), which the rating frames as a distribution warning rather than accumulation. The cash-engine pillar also sits low because the source data reports zero ROIC and zero FCF yield, meaning the rating does not credit the company with any current cash return on capital. The balance sheet is the relatively stronger pillar: the forensic metrics (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) sit in a middle range rather than signaling distress. Valuation tradeoffs cannot be assessed directly because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data; the investor therefore has no earnings-based anchor for the $5.85 price. The Macro Regime pillar reflects a beta of 1.0, which by itself indicates market-level sensitivity rather than amplified volatility. Upside drivers would have to come from catalysts not yet reflected in cash flows, and the source data does not quantify those. This is an analytical summary, not personalized financial advice.

Per the recent news wire, the headlines include: a TradingView estimates report; a Stock Titan item on a subsidiary's robotaxi recharging system; a ChartMill unusual-volume mention; an Investing.com item stating patient recruitment completed for an AUD trial segment; a Benzinga pre-market mention; and a Quiver Quantitative item stating recruitment completed for the first Part B cohort in a Phase I/IIa trial of CMND-100 for alcohol use disorder. All six items are flagged YELLOW with the impact label MARKET WIRE. Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Risk watch items: the news flow is largely descriptive, and the source data does not report trial results or regulatory outcomes.

Per the Butterfly Supply-Chain Graph, the supply chain is NONE and no butterfly links are recorded. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. Investors should note that the only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations.

• What are CMND's reported revenue, operating income, net income, and cash flow across periods? The financials section is NONE.
• What is the status and outcome of the CMND-100 alcohol use disorder trial beyond recruitment completion?
• What are the consensus rating and price targets? The analyst data section is NONE.
• Who are the institutional and insider holders, and what are the 13F and Form 4 positions? The holders section is NONE.
• What drives the 52-week range of $5.25 - $2688, and what explains the gap between that range and the current price?